Binding to COMP Reduces the BMP2 Dose for Spinal Fusion in a Rat Model.

Authors:
Motasem Refaat
Motasem Refaat
School of Medicine
United States
Eric O Klineberg
Eric O Klineberg
University of California
United States
Tanya C Garcia
Tanya C Garcia
University of California Davis
Prof. Dominik R Haudenschild, Ph.D.
Prof. Dominik R Haudenschild, Ph.D.
University of California Davis Medical Center
Professor
Arthritis Research
Sacramento, CA | United States

Spine (Phila Pa 1976) 2016 Jul;41(14):E829-36

*Lawrence J. Ellison Musculoskeletal Research Center, Department of Orthopaedic Surgery, University of California Davis, Davis, CA †Department of Biomedical Engineering, University of California Davis, Davis, CA ‡J.D. Wheat Veterinary Orthopaedic Laboratory, School of Veterinary Medicine, University of California Davis, One Shields Avenue, Davis, CA.

Study Design: The aim of this study is to test the effect of cartilage oligomeric matrix protein (COMP) on enhancing rhBMP-2 induced spinal fusion in a prospective 8-week interventional trial of spinal fusion in rats.

Objective: To determine whether the amount of bone morphogenetic protein-2 (BMP-2) required to achieve spinal fusion in a pre-clinical model can be reduced by the addition of COMP.

Summary Of Background Data: BMPs are applied clinically at supraphysiological doses to promote spinal fusion by inducing osseous growth, but dose-related limitations include ectopic bone formation and local inflammatory reactions. COMP is a matricellular BMP-binding protein expressed during endochondral ossification and fracture healing. In vitro studies demonstrate enhanced activity of BMP bound to COMP. We hypothesized that BMP bound to COMP could achieve equivalent spinal fusion rates at lower doses and with fewer complications.

Methods: Posterolateral intertransverse process spinal fusion at L4 to L5 was performed in 36 Lewis rats. COMP (10 μg) was tested with or without "low-dose" rhBMP-2 (2 μg), and the results were compared with the "low-dose" (2 μg rhBMP-2) and "high-dose" (10 μg rhBMP-2) groups. All groups utilized insoluble collagen bone matrix carrier (ICBM). Fusion was evaluated by radiology, histology, and manual palpation. BMP release kinetics were evaluated in vitro.

Results: Fusion grading of microCT images demonstrated that the fusion rate with the COMP+LoBMP was statistically equivalent to HiBMP, and significantly better than LoBMP without COMP. These results were confirmed with radiographs and manual palpation. BMP release kinetics suggest that COMP increased local concentrations of BMP due to decreased growth factor retention on the scaffold.

Conclusion: COMP enhances BMP-induced bone formation, enabling lower doses of BMP to achieve the same level of spinal fusion. COMP may function by affecting the availability and biological presentation of BMP-2. A decrease of BMP-2 required for fusion may reduce dose-related adverse effects, surgical costs, and improve clinical outcomes.

Level Of Evidence: N/A.

Download full-text PDF

Source
http://dx.doi.org/10.1097/BRS.0000000000001408DOI Listing

Still can't find the full text of the article?

We can help you send a request to the authors directly.
July 2016
181 Reads
1 Citation
2.300 Impact Factor

Publication Analysis

Top Keywords

spinal fusion
32
fusion
12
comp
9
palpation bmp
8
release kinetics
8
manual palpation
8
lower doses
8
spinal
8
bound comp
8
bmp release
8
bone formation
8
bmp-2 required
8
bmp bound
8
bmp
6
achieve equivalent
4
equivalent spinal
4
enhanced activity
4
activity bmp
4
comp hypothesized
4
hypothesized bmp
4

Similar Publications